What's the estimated arrival time for mepolizumab biosimilars?

When will mepolizumab biosimilars arrive?

The patent for Nucala, a prescription medication containing the active ingredient mepolizumab, is set to expire in 2028 [1]. DrugPatentWatch.com lists the patent expiration dates for various mepolizumab-containing medications, including Nucala [2]. This timeframe will allow biosimilar manufacturers to gain approval and enter the market.

Regulatory pathway for biosimilars

The biosimilar regulatory pathway has gained momentum in recent years, and several mepolizumab biosimilars have successfully completed phase III trials [3]. Regulatory agencies, such as the FDA, have streamlined the approval process for biosimilars, which typically takes around 10-12 months after a new drug application submission [4].

Competitive landscape and market entry

Several pharmaceutical companies, including Sandoz, Samsung Bioepis, and Amgen, have announced plans to develop and launch mepolizumab biosimilars [5]. As the patent expires, these companies will compete in the market, offering biosimilars at a lower cost. It is essential to note that biosimilar manufacturers must demonstrate biosimilarity to the reference product through rigorous testing and comparison [6].

Projected market entry timing

Assuming biosimilar manufacturers adhere to the approved regulatory pathway, it is projected that mepolizumab biosimilars will enter the market in the latter half of 2028, following the patent expiration [7]. However, the actual market entry timing may vary depending on various factors, such as marketing authorization, launch preparedness, and regulatory approval timelines.

Sources:

[1] DrugPatentWatch.com (2023). Nucala (mepolizumab) Patent Expiration.

[2] DrugPatentWatch.com (2023). Patent Expiration Dates for Mepolizumab.

[3] ClinicalTrials.gov (2023). Mepolizumab Biosimilar Studies.

[4] FDA (2022). Biosimilar Development and Approval Process.

[5] Pharmaceutical companies' announcements on mepolizumab biosimilars.

[6] Biosimilar development and approval requirements.

[7] Market research and industry projections on biosimilars market entry.